|
| 37743097 | Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias. | Br J Haematol | 2024 |
| 37743097 | Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias. | Br J Haematol | 2024 |
| 35984639 | Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. | Blood Adv | 2023 |
| 36179268 | Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions. | Blood | 2023 |
| 35984639 | Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. | Blood Adv | 2023 |
| 37584517 | Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors. | Cancer Res | 2023 |
| 37977148 | A longitudinal single-cell atlas of treatment response in pediatric AML. | Cancer Cell | 2023 |
| 37693371 | Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy. | bioRxiv | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 36585521 | High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia. | Leukemia | 2023 |
| 37021537 | Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network. | Haematologica | 2023 |
| 37019972 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | Nat Commun | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 37390387 | Reply to Z.R. McCaw et al. | J Clin Oncol | 2023 |
| 36634304 | CREBBP alterations are associated with a poor prognosis in de novo AML. | Blood | 2023 |
| 37452102 | Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. | Leukemia | 2023 |
| 37315172 | Donor bone marrow-derived macrophage engraftment into the central nervous system of patients following allogeneic transplantation. | Blood Adv | 2023 |
| 37380943 | PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing. | BMC Bioinformatics | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 36993526 | DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune Components. | Res Sq | 2023 |
| 36927800 | Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients. | Biomark Res | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 37480164 | Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. | Pediatr Blood Cancer | 2023 |
| 36720638 | Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia. | Pediatr Blood Cancer | 2023 |
| 36595452 | Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. | Blood Adv | 2023 |
| 37480164 | Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. | Pediatr Blood Cancer | 2023 |
| 37584517 | Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors. | Cancer Res | 2023 |
| 37693371 | Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy. | bioRxiv | 2023 |
| 37977148 | A longitudinal single-cell atlas of treatment response in pediatric AML. | Cancer Cell | 2023 |
| 36993526 | DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune Components. | Res Sq | 2023 |
| 37390387 | Reply to Z.R. McCaw et al. | J Clin Oncol | 2023 |
| 37021537 | Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network. | Haematologica | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 37019972 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | Nat Commun | 2023 |
| 37452102 | Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. | Leukemia | 2023 |
| 37315172 | Donor bone marrow-derived macrophage engraftment into the central nervous system of patients following allogeneic transplantation. | Blood Adv | 2023 |
| 37380943 | PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing. | BMC Bioinformatics | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 36720638 | Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia. | Pediatr Blood Cancer | 2023 |
| 36585521 | High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia. | Leukemia | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36634304 | CREBBP alterations are associated with a poor prognosis in de novo AML. | Blood | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 36595452 | Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. | Blood Adv | 2023 |
| 36927800 | Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients. | Biomark Res | 2023 |
| 36179268 | Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions. | Blood | 2023 |